Current and emerging therapeutic approaches to hepatitis C infection

Expert Review of Anti-Infective Therapy

Volumn 1, Issue 3, 2003, Pages 441-454

  Durantel, David ^a   Escuret, Vanessa ^a   Zoulim, Fabien ^a  

^a INSERM   (France)

Author keywords

Combination therapy; Hepatitis C virus; Interferon; Pegylated interferon

Indexed keywords

2' BETA METHYLGUANOSINE; 3 [((2 DIPROPYLMINO)ETHYL)THIO] 5H 1,2,4 TRIAZINO[5,6B]INDOLE; ALKOVIR; ALPHA INTERFERON; AMANTADINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; CARBOHYDRATE DERIVATIVE; CILUPREVIR; COMPLEMENTARY RNA; CONSENSUS INTERFERON; CONTRACEPTIVE AGENT; DPC AB914400; GLUCOVIR; HEPTAZYME; ISIS 14803; NM 107; PARACETAMOL; PEGASIS; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; REBETROL; RIBAVIRIN; RIBONUCLEOSIDE DERIVATIVE; RIBOZYME; RNA DIRECTED DNA POLYMERASE INHIBITOR; RNA HELICASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALOPICITABINE; VP 32947; VP 50406; VX 950;

ALOPECIA; ASTHENIA; AUTOIMMUNE DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; CYTOPENIA; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESPONSE; DRUG SCREENING; DRUG TARGETING; EPILEPSY; FLU LIKE SYNDROME; HEALTH HAZARD; HEMOGLOBINOPATHY; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERURICEMIA; INFECTION CONTROL; ISCHEMIC HEART DISEASE; LACTIC ACIDOSIS; LIVER TOXICITY; LUNG DISEASE; MENTAL DISEASE; MOUSE; NEUTROPENIA; NONHUMAN; REVIEW; SIDE EFFECT; TERATOGENICITY; THROMBOCYTOPENIA; THYROIDITIS; WEIGHT REDUCTION;

EID: 3042703977     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.1.3.441     Document Type: Review

References (102)

1. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 26(3 Suppl. 1), 15S-20S (1997).
2. Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N. Engl. J. Med. 1 336(5), 347-356 (1997).
3. Di Bisceglie AM, McHutchison J, Rice CM. New therapeutic strategies for hepatitis C. Hepatology 35(1), 224-231 (2002).
4. Choo Q, Kuo G, Weiner AJ et al. Isolation of a cDNA clone derived from a blood borne non-A, non-B viral hepatitis genome. Science 244, 359-362 (1989).
5. Bartenschlager R, Hepatitis C virus replicons: potential role for drug development. Nature Rev. Drug Discov. 1(11), 911-916 (2002).
6. Bartenschlager R, Lohmann V. Replication of hepatitis C virus. J. Genet. Virol. 81(Pt 7), 1631-1648 (2000).
7. Dubuisson J, Penin F, Moradpour D. Interaction of hepatitis C virus proteins with host cell membranes and lipids. Trends Cell. Biol. 12(11), 517-523 (2002).
8. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197(5), 633-642 (2003).
9. Dubuisson J, Folding, assembly and subcellular localization of hepatitis C virus glycoproteins. Curr. Top. Microbiol. Immunol. 242, 135-148 (2000).
10. Grakoui A, Hanson HL, Rice CM. Bad time for Bonzo? Experimental models of hepatitis C virus infection, replication and pathogenesis. Hepatology 33(3), 489-495 (2001).
11. Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 30(3), 595-601 (1999).
12. de la Torre JC, Mallory M, Brot M et al. Viral persistence in neurons alters synaptic plasticity and cognitive functions without destruction of brain cells. Virology 220(2), 508-515 (1996).
13. Oldstone MB. Molecular anatomy of viral persistence. J. Virol. 65(12), 6381-6386 (1991).
14. Pawlotsky JM. Hepatitis C virus infection: virus/host interactions. J. Viral Hepatitis 5(Suppl. 1), 3-8 (1998).
15. Andre P, Komurian-Pradel F, Deforges S et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J. Virol. 76(14), 6919-6928 (2002).
16. Afonso AM, Jiang J, Penin F et al. Nonrandom distribution of hepatitis C virus quasispecies in plasma and peripheral blood mononuclear cell subsets. J. Virol. 73(11), 9213-9221 (1999).
17. Goutagny N, Fatmi A, De Ledinghen V et al. Evidence of viral replication in circulating dendritic cells during hepatitis C virus infection. J. Infect. Dis. 187(12), 1951-1958 (2003).
18. Bain C, Fatmi A, Zoulim F et al. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 120(2), 512-524 (2001).
19. + lymphocytes using class I peptide tetramers. Rev. Med. Virol. 11(1), 11-22 (2001).
20. + T-lymphocytes after infection with hepatitis C virus. J. Virol. 75(12), 5550-5558 (2001).
21. Zoulim F, Chevallier M, Maynard M et al. Clinical consequences of hepatitis C virus infection. Rev. Med. Virol. 13(1), 57-68 (2003).
22. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Lancet 349(9055), 825-832 (1997).
23. Prieto M, Berenguer M, Rayon JM et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 29(1), 250-256 (1999).
24. Berenguer M, Prieto M, Cordoba J et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J. Hepatol. 28(5), 756-763 (1998).
25. Marcellin P, Benhamou JP. [Natural history of hepatitis C virus infection]. Pathol. Biol. (Paris), 43(8), 669-673 (1995).
26. Dusheiko G, Schmilovitz-Weiss H, Brown D et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 19, 13-18 (1994).
27. Poynard T, Ratziu V, Charlotte F et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J. Hepatol. 34(5), 730-739 (2001).
28. 2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 32(3), 647-653 (2000).
29. 2b as initial treatment for chronic hepatitis C. Hepatology 34(2), 395-403 (2001).
30. 2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 343(23), 1673-1680 (2000).
31. 2a in patients with chronic hepatitis C. N. Engl. J. Med. 343(23), 1666-1672 (2000).
32. 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286), 958-965 (2001).
33. 2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347(13), 975-982 (2002).
34. 2a (40kD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a Phase III, randomized, double-blind multicentre study examining effect of durationof treatment and RBV dose. J. Hepatol. 36(1 Suppl. 3), 17-18 (2002).
35. Pawlotsky JM. Hepatitis C virus resistance to antiviral therapy. Hepatology 32(5), 889-896 (2000).
36. 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) [see comments]. Lancet 352(9138), 1426-1432 (1998).
37. Tam RC, Pai B, Bard J et al. Ribavirin polarizes human T-cell responses towards a Type 1 cytokine profile. J. Hepatol. 30(3), 376-382 (1999).
38. Hultgren C, Milich DR, Weiland O et al. The antiviral compound ribavirin modulates the T-helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J. Genet. Virol. 79(Pt 10), 2381-2391 (1998).
39. Lanford RE, Chavez D, Guerra B et al. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J. Virol. 75(17), 8074-8081 (2001).
40. Querenghi F, Yu Q, Billaud G et al. Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy. J. Viral Hepatitis 8(2), 120-131 (2001).
41. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 282(5386), 103-107 (1998).
42. 2. Gastroenterology 120(6), 1438-1447 (2001).
43. Zeuzem S, Schmidt JM, Lee JH et al. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon-α on viral turnover. Hepatology 28(1), 245-252 (1998).
44. Guo JT, Bichko VV, Seeger C. Effect of interferon-α on the hepatitis C virus replicon. J. Virol. 75(18), 8516-8523 (2001).
45. 2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group [see comments]. N. Engl. J. Med. 339(21), 1493-1499 (1998).
46. 2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122(5), 1303-1313 (2002).
47. 2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 32(5), 1131-1137 (2000).
48. 2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 52(3), 425-432 (2003).
49. 2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am. J. Gastroenterol. 95(6), 1524-1530 (2000).
50. 2a therapy in cryoglobulinemia associated with hepatitis C virus. N. Engl. J. Med. 330(11), 751-756 (1994).
51. Hermine O, Lefrere F, Bronowicki JP et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N. Engl. J. Med. 347, 891-94 (2002).
52. Salmon-Ceron D, Lassalle R, Pruvost A et al. Interferon-ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) Type 1 level in patients coinfected with hiv and hepatitis c virus: A CORIST-ANRS HC1 trial. Clin. Infect. Dis. 36(10), 1295-1304 (2003).
53. 2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 17(7), 1023-1028 (2003).
54. 2b. N. Engl. J. Med. 345(20), 1452-1457 (2001).
55. Gerlach JT, Diepolder HM, Zachoval R et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 125(1), 80-88 (2003).
56. 2b plus ribavirin: study of sixteen patients]. Gastroenterol. Clin. Biol. 27(3), 294-299 (2003).
57. Heathcote EJ, James S, Mullen KD et al. Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. The Consensus Interferon Study Group. Hepatology 30(2), 562-566 (1999).
58. Pellicano R, Palmas F, Cariti G et al. Retreatment with interferon-β of patients with chronic hepatitis C virus infection. Eur. J. Gastroenterol. Hepatol. 14(12), 1377-1382 (2002).
59. Cheney IW, Lai VC, Zhong W et al. Comparative analysis of antihepatitis C virus activity and gene expression mediated by α-, β- and γ- interferons. J. Virol. 76(21), 11148-11154 (2002).
60. Lanford RE, Guerra B, Lee H et al. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha and ribavirin in hepatitis C virus subgenomic replicons. J. Virol. 77(2), 1092-1104 (2003).
61. Geiss GK, Carter VS, He Y et al. Gene expression profiling of the cellular transcriptional network regulated by interferon-α /β and its partial attenuation by the hepatitis C virus nonstructural 5A protein. J. Virol. 77(11), 6367-6375 (2003).
62. Zhu H, Zhao H, Collins CD et al. Gene expression associated with interferon-α antiviral activity in an HCV replicon cell line. Hepatology 37(5), 1180-1188 (2003).
63. Shimizu YK, Purcell RH, Yoshikura H. Correlation between the infectivity of hepatitis C virus in vivo and its infectivity in vitro. Proc. Natl Acad. Sci. USA 90(13), 6037-6041 (1993).
64. Major ME, Mihalik K, Fernandez J et al. Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus. J. Virol. 73(4), 3317-3325 (1999).
65. Farci P, Shimoda A, Wong D et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. PG. Proc. Natl Acad. Sci. USA 93(26) (1996).
66. Farci P, Alter HJ, Govindarajan S et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 258(5079), 135-140 (1992).
67. Kolykhalov AA, Agapov EV, Blight KJ et al. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 277(5325), 570-574 (1997).
68. Ilan E, Arazi J, Nussbaum O et al. The hepatitis C virus (HCV) - Trimera mouse: a model for evaluation of agents against HCV. J. Infect. Dis. 185(2), 153-161 (2002).
69. Dagan S, Eren R. Therapeutic antibodies against viral hepatitis. Curr. Opin. Mol. Ther. 5(2), 148-155 (2003).
70. Mercer DF, Schiller DE, Elliott JF et al. Hepatitis C virus replication in mice with chimeric human livers. Nature Med. 7(8), 927-933 (2001).
71. Zitzmann N, Mehta AS, Carrouee S et al. Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum antihepatitis virus agents. Proc. Natl Acad. Sci. USA 96(21), 11878-11882 (1999).
72. Durantel D, Branza-Nichita N, Carrouee-Durantel S et al. Study of the mechanism of antiviral action of iminosugar derivatives against bovine viral diarrhea virus. J. Virol. 75(19), 8987-8998 (2001).
73. Bukh J, Apgar CL, Govindarajan S et al. Host range studies of GB virus-B hepatitis agent, the closest relative of hepatitis C virus, in New World monkeys and chimpanzees. J. Med. Virol. 65(4) 694-697 (2001).
74. Beames B, Chavez D, Guerra B et al. Development of a primary tamarin hepatocyte culture system for GB virus-B: a surrogate model for hepatitis C virus. J. Virol. 74(24) 11764-11772 (2000).
75. De Francesco R, Rice CM. New therapies on the horizon for hepatitis C: are we close? Clin. Liver Dis. 7(1), 211-242 (2003).
76. Ideo G, Bellobuono A. New therapies for the treatment of chronic hepatitis C. Curr. Pharm. Des. 8(11), 959-966 (2002).
77. Locarnini SA, Bartholomeusz A. Advances in hepatitis C: what is coming in the next 5 years? J. Gastroenterol. Hepatol. 17(4), 442-447 (2002).
78. McHutchison JG, Patel K. Future therapy of hepatitis C. Hepatology 36(5 Suppl. 1), S245-S252 (2002).
79. Ito T, Tahara SM, and Lai MM. The 3′-untranslated region of hepatitis C virus RNA enhances translation from an internal ribosomal entry site. J. Virol. 72(11), 8789-8796 (1998).
80. Witherell GW. ISIS-14803 (Isis Pharmaceuticals). Curr. Opin. Investig. Drugs 2(11), 1523-1529 (2001).
81. Jubin R. Hepatitis C IRES: translating translation into a therapeutic target. Curr. Opin. Mol. Ther. 3(3), 278-287 (2001).
82. Yokota T, Sakamoto N, Enomoto N et al. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep. 4(6), 602-608 (2003).
83. Kapadia SB, Brideau-Andersen A, Chisari FV. Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc. Natl Acad. Sci. USA 100(4), 2014-2018 (2003).
84. Narjes F, Koch U, Steinkuhler C. Recent developments in the discovery of hepatitis C virus serine protease inhibitors-towards a new class of antiviral agents? Expert Opin. Investig. Drugs 12(2), 153-163 (2003).
85. De Francesco R, Steinkuhler C. Structure and function of the hepatitis C virus NS3-NS4A serine proteinase. Curr. Top. Microbiol. Immunol. 242, 149-169 (2000).
86. Pause A, Kukolj G, Bailey M et al. An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA. J. Biol. Chem. 278(22), 20374-20380 (2003).
87. Kwong AD, Kim JL, Lin C. Structure and function of hepatitis C virus NS3 helicase. Curr. Top. Microbiol. Immunol. 242, 171-196 (2000).
88. Lesburg CA, Cable MB, Ferrari E et al. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nature Struct. Biol. 6(10), 937-943 (1999).
89. Wang QM, Hockman MA, Staschke K et al. Oligomerization and co-operative RNA synthesis activity of hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 76(8), 3865-3872 (2002).
90. Walker MP, Appleby TC, Zhong W et al. Hepatitis C virus therapies: current treatments, targets and future perspectives. Antiviral Chem. Chemother. 14(1), 1-21 (2003).
91. De Francesco R, Tomei L, Altamura S, Summa V, Migliaccio G. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res. 58(1), 1-16 (2003).
92. Hagedorn CH, van Beers EH, De Staercke C. Hepatitis C virus RNA-dependent RNA polymerase (NS5B polymerase). Curr. Top. Microbiol. Immunol. 242, 225-260 (2000).
93. Carroll SS, Tomassini JE, Bosserman M et al. Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J. Biol. Chem. 278(14), 11979-11984 (2003).
94. Stuyver LJ, Whitaker T, McBrayer TR et al. Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob. Agents Chemother. 47(1), 244-254 (2003).
95. Maag D, Castro C, Hong Z, Cameron CE et al. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J. Biol. Chem 276(49), 46094-46098 (2001).
96. Wang M. Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J. Biol. Chem. 278(11), 9489-9495 (2003).
97. Biroccio A, Hamm J, Incitri I et al. Selection of RNA aptamers that are specific and high-affinity ligands of the hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 76(8), 3688-3696 (2000).
98. Dhanak D, Duffy KJ, Johnston VK et al. Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J. Biol. Chem. 277(41), 38322-38327 (2002).
99. Gu B, Johnston VK, Gutshall LL et al. Arresting initiation of hepatitis C virus RNA synthesis using heterocyclic derivatives. J. Biol. Chem. 278(19), 16602-16607 (2003).
100. Moradpour D, Bieck E, Hugle T et al. Functional properties of a monoclonal antibody inhibiting the hepatitis C virus RNA-dependent RNA polymerase. J. Biol. Chem. 277(1), 593-601 (2002).
101. Pavlovic D, Neville DC, Argaud O et al. The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc. Natl Acad. Sci. USA 100(10), 6104-618 (2003).
102. Griffin SD, Beales LP, Clarke DS et al. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Lett. 535(1-3), 34-38 (2003).